TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Inhalation of Low Concentration of CO2 in Preterm Infants Not Responding to Caffeine for the Treatment of Apnea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* gestational age at birth \< 33 weeks~* on caffeine treatment for apnea of prematurity at a maintenance dose of 5 mg/kg/day~* having apnea of prematurity (at least 5 self-resolved apneas or 2 apneas requiring intervention/12 hours)~Exclusion Criteria:~* on mechanical ventilation~* presence of congenital anomalies, sepsis or other known causes of apnea~* failure to obtain parental consent

- Gender: ALL
- Minimum Age: 3 Days
- Maximum Age: 60 Days
- Healthy Volunteers: f

Study Arms:
- Inhalation of low concentration of CO2 (Type: EXPERIMENTAL): None
- caffeine only (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intraoperative Fluid Management Based on Arterial Pulse Pressure Variation During High-Risk Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Medico-surgical pre-operative decision of post-operative ICU admission (because of co-morbidities or/and the surgical procedure)~* Age \> 18 yr~* Elective surgery~Exclusion criteria:~* No informed consent~* Cardiac arrhythmias~* Body mass index \> 40~* Patients undergoing surgery with an open thorax~* Patients undergoing neurosurgery~* Enrolment in any other protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Ejaculation Preservation After Laser Enucleation Prostate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 40 years and older who have signed their consent to participate in the study~* Patient with preserved cognitive functions~* Patient with BPH characterised by an IPSS score ≥ 12, a Qmax ≤ 15 ml/s and an ultrasound-assessed prostate volume between 40 and 150 cc~* Patient for whom an indication for prostatic resection by HoLEP has been made,~* A patient who is sexually active and willing to maintain sexual activity after surgery~* Patient affiliated to a social security system or beneficiary of such a system~Exclusion Criteria:~* History of prostate surgery or prostate radiotherapy~* Urethral stenosis~* Cancer or a history of cancer~* Patient with a life expectancy of less than 2 years~* Patient refusing partial surgery~* History of vasectomy, erectile dysfunction or ejaculation~* Mental deficiency or any other reason that may hinder the understanding or the strict application of the protocol~* Patient under court protection, guardianship or curatorship~* Patient already included in another therapeutic study protocol or having participated in another trial in the previous three months

- Gender: MALE
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HoLEP classic (Type: OTHER): Standard HoLEP prostate resection procedure with enucleation of all three lobes (3-lobe, 2-lobe or monobloc technique).
- HoLEP with median lobe preservation (Type: EXPERIMENTAL): Enucleation of the lateral lobes and preservation of the medial tissue between the bladder neck and Veru montanum.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Moxonidine in Patients Undergoing Vascular Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* abdominal aortic or peripheral vascular surgery~Exclusion Criteria:~* unstable angina,~* severe symptomatic heart failure (NYHA IV)~* systolic blood pressure at rest \< 100 mmHg~* bradycardia (\<50/min)~* higher grade AV heart block~* creatinine clearance \< 30 ml/min~* pregnancy~* no consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- I (Type: ACTIVE_COMPARATOR): moxonidine group
- II (Type: PLACEBO_COMPARATOR): placebo group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Femoral Nerve Block With Bupivacaine and Adjuvant Dexamethasone in Patients With Hip Fracture

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical suspicion of hip fracture~* Age ≥ 55 years~* Mentally capable of comprehending and using verbal pain score~* Mentally capable of differentiating between pain from the fractured hip and pain from other locations~* Mentally capable of understanding the given information~* Arrival in the emergency room at times when one of the doctors who do the nerve blocks for this investigation are on call~* Verbal pain score (0-10) ≥ 7 with passive leg raise of the fractured leg at the time of inclusion~* Patients informed consent~Exclusion Criteria:~* Hip fracture not confirmed by x-ray~* Weight \< 40 kg~* Verbal pain score \> 3, 30 minutes after the nerve block~* Verbal pain score \> 5 with passive leg raise, 30 minutes after the nerve block~* Patient has previously been included in this trial~* Ongoing pre traumatic treatment with parenteral or intravenous adrenocortical hormone~* Verbal pain score \> 3 from other locations than the fractured hip~* If the patient wishes to be excluded~* Allergy to local anesthetics or adrenocortical hormone~* Visible infection in the area of the point of needle injection~* Acute inability to comprehend and use verbal pain score

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Saline (Type: PLACEBO_COMPARATOR): Bupivacaine with adrenaline with 2 ml. of Saline added
- Dexamethasone (Type: EXPERIMENTAL): Bupivacaine with adrenaline with 2 ml. of Dexamethasone added

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Adaptated Physical Activity in Cancerology

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women aged 18 to 75 years (included)~* Patient with a breast tumor, regardless of the stage and size (except metastatic patients)~* Patient with a local recurrence of breast cancer~* Patient with a second non-metastatic breast cancer~* Breast cancer treated, regardless of the surgery, at least by radiotherapy, chemotherapy (neoadjuvant or adjuvant) +/- targeted therapy~* A mandatory social security affiliation.~* Obtaining informed consent in writing, signed and dated.~* Medical certificate of fitness to practice physical (issued by the medical oncologist)~Exclusion Criteria:~* Cancer other than breast cancer and / or associated with breast cancer~* Metastatic Cancer~* in case of surgery before treatment, delay before beginning treatment inferior to 1 month post-surgery~* Men~* Woman pregnant~* Patient with cognitive or psychiatric disorders~* Patients suffering from disability~* Significant alterations in nutritional status (malnutrition with BMI \<19, obese with BMI\> 40, BMI)~* Cardiac contraindication to physical activity~* Knowledge and understanding of the French language enough not to learn the correct way of self-administered questionnaires or respond to questioning~* Participation in another clinical study with a similar objective~* Inability to reach the centers where physical activity takes place

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Arm A with physical activity during the treatment (Type: OTHER): In the arm A, patients will realise physical activity during the treatment. Blood samples will be realised. Questionnaries will be given to the patients.
- Arm B with physical activity after the treatment (Type: OTHER): In the arm B, the physical activity will be realised after treatment. Blood samples will be realised. Questionnaries will be given to the patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cannabis for Spasticity in Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of clinically definite multiple sclerosis as defined by Poser criteria~* Primary or secondary disease course~* Moderate or severe spasticity~* Age 21 or older~Exclusion Criteria:~* Preexisting pulmonary conditions, including poorly controlled asthma, chronic bronchitis, emphysema, bronchiectasis, and other significant pulmonary disorders~* Preexisting cardiac conditions, including ischemic heart disease, congestive heart failure, and other significant cardiac disorders~* Inability to abstain from tobacco or marijuana smoking, or use of alcohol or sedative or hypnotic medications during the duration of the study~* Past history of abuse of recreational drugs, including marijuana and alcohol in the last 12 months~* History of or currently meets DSM-IV criteria for dependence on cannabis~* Use of cannabis, marijuana, or THC in the last two weeks~* Preexisting dementia, mania, depression, or schizophrenia or other poorly controlled psychiatric illness~* Exacerbation of MS within 30 days prior to screenin visit~* Current use of cyclophosphamide, mitoxanthrone, or cladribine~* Arthritis, bony and soft tissue disorders interfering with spasticity measures~* Inability to provide informed consent~* Recent cannabis use of more than twice per week one month prior to study entry

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Double-balloon Colonoscopy to Increase Colonoscopy Completion Rate

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Failed cecal intubation during conventional colonoscopy due to technical difficulties~Exclusion Criteria:~* Failed cecal intubation due to insufficient bowel preparation~* Stenotic colonic lesions~* Patients decline~* Pregnancy~* Persons younger than 18 years~* Persons unable to comprehend the information given

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- DBC (Type: EXPERIMENTAL): Double balloon colonoscopy will be attempted in cases where conventional colonoscopy failed due to technical difficulties such as looping or redundant colonic segments.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Observational Study of Rebismart®2.0 + MSdialog™ in Subjects With Remitting Multiple Sclerosis (ADHERQOL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with RRMS according to McDonald criteria 2010~* Relapse free within 30 days before Baseline data collection~* Treatment with Rebif for 6 months or more prior to informed consent~* Already using RebiSmart®2.0 + MSdialog™ for patient reported outcome (PRO) assessments (at least once prior to informed consent)~* Females of childbearing potential must be willing to use appropriate contraception for the duration of the study~* EDSS score less than (\<) 6~* Written informed consent obtained prior to any protocol-required data collection~Exclusion Criteria:~* Participation in other studies within 30 days before Baseline~* Female who is pregnant or breast feeding~* Significant psychiatric symptoms that, in the opinion of the Investigator, would impact subject ability to comply with treatment (as per standard clinical practice)~* Any contraindication for Interferon (IFN) beta-1a therapy as per Summary of Product Characteristics (SPC)~* Administration of any Multiple Sclerosis (MS) therapy, other than Rebif, within 6 months prior to informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Relapsing-remitting Multiple Sclerosis (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of a Case Management Intervention for Alcohol Use-Related Problems in Frequent Users of an Emergency Department

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 5 or more attendances during the previous 12 months at the Emergency Department of Hospital Clínic de Barcelona~* an AUDIT-C score higher than 5 points for men and 4 for women~* Patients who accept to participate in the study and give informed consent~* Exists valid contact information to reach patient in the future.~Exclusion Criteria:~* There is psychopathology that prevents study comprehension and/or future participation (i.e. cognitive impairment, acutely psychotic, acutely confused, intoxicated...)~* Patients who present medical conditions that predict that will not be able to participate in follow-up.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Participants will receive an intensive Case Management (CM) intervention conducted by a multidisciplinary team during 2 months. They will attend weekly or biweekly appointments with the CM team, the interviews will last approximately 30 minutes and will be conducted based on Motivational Interviewing techniques in order to explore values and needs and to enhance motivation to reduce alcohol use and self-efficacy.~Receiving the CM intervention doesn't exclude treatment as usual.
- Control (Type: NO_INTERVENTION): Only treatment as usual in the Emergency Department (and in the Health and Social Services Network).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of New Diagnostic Methods of Cardio-embolic Related (Atrial Fibrillation) Cerebral Infarction

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient over 18~* Patient having a CHADS-VAsc Score ≥ 2;~* Patient hospitalized for a secondary established ischemic accident in an atrial fibrillation not anticoagulated (INR\<2 and/or receiving antiplatelet (aspirin, clopidogrel)) for less than 14 days;~* Patient affiliated to a national insurance scheme or beneficiary~* Patient having given a written consent~Exclusion Criteria:~* Patient presenting cognitive disorders incompatible with the planned examinations (MRI / SCANNER).~* Pacemaker or implantable defibrillator, or other contraindication in the MRI (metallic eye brightness, intra cerebral clip).~* Contraindication in injected scanner.~* Current pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stroke (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Irinotecan, Capecitabine and Avastin for Metastatic Colorectal Cancer as Salvage Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed locally advanced or metastatic colorectal cancer~* Measurable or evaluable disease according to the Response Evaluation Criteria in Solid Tumors~* ECOG performance status ≤ 2~* Age 18 - 72 years~* Patients who progress after 1st line therapy with FOLFOX/AVASTIN~* Adequate liver (Bilirubin ≤ 1.5 upper normal limit, SGOT/SGPT ≤ 4 upper normal limit, ALP ≤ 2.5 upper normal limit) renal (Creatinine ≤ 1.5 upper normal limit) and bone marrow (ANC ≥ 1,500/mm3, PLT ≥100,000/mm3) function~* Patients must be able to understand the nature of this study~* Written informed consent~Exclusion Criteria:~* History of serious cardiac disease (unstable angina, congestive heart failure,uncontrolled cardiac arrhythmias)~* History of myocardial infarction or stroke within 6 months~* Clinically significant peripheral vascular disease~* History of abdominal fistula, gastrointestinal perforation or intraabdominal abscess within 28 days prior to Day 0~* Major surgical procedure, open biopsy, or significant traumatic injury within 30 days prior to Day 1~* Presence of central nervous system or brain metastasis~* Evidence of bleeding diathesis or coagulopathy~* Blood pressure \> 150/100 mmHg~* Pregnant or lactating woman~* Life expectancy \< 3 months~* Previous radiotherapy within the last 4 weeks or \> 25% of bone marrow~* Metastatic infiltration of the liver \> 50%~* Patients with chronic diarrhea (at least for 3 months) or partial bowel obstruction or total colectomy~* Active infection requiring antibiotics on Day 1~* Second primary malignancy, except for non-melanoma skin cancer and in situ cervical cancer~* Psychiatric illness or social situation that would preclude study compliance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 72 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): XELIRI/Avastin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hospitalized with moderate, severe, or early critical COVID-19 illness diagnosed by RT- PCR~* Acute liver injury (including acute on chronic liver disease) or acute kidney injury or moderate COVID-19 pneumonia~Exclusion Criteria:~* Critical COVID-19 illness (MAP \< 60 mm Hg, on mechanical ventilator for ≥ 5 days)~* On maintenance hemodialysis or peritoneal dialysis~* Child Pugh C cirrhosis~* Hepatorenal syndrome~* Ascites and/or hepatic encephalopathy~* History of end stage renal disease or CKD with eGFR \< 15 mL/min/1.73m2~* Women who are pregnant or breast feeding~* Receipt of other concomitant experimental therapies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- DUR-928 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Use of Self Retaining Sutures in Open and Laparoscopic Partial Nephrectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* any person who is being treated for kidney cancer with partial nephrectomy.~Exclusion Criteria:~* those from whom we cannot obtain adequate informed consent.~* those that are converted from partial to radical nephrectomy intraoperatively.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Quill knotless tissue-closure device (Type: EXPERIMENTAL): During partial nephrectomy participants in this group will receive the Quill Knotless Tissue-Closure device (Angiotech Pharmaceuticals) to close the central defect in their kidney.
- 2-0 absorbable vicryl suture (Type: ACTIVE_COMPARATOR): Participants in this group will be receiving traditional 2-0 vicryl sutures (Ethicon) during partial nephrectomy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues